Abstract
Background This study aimed to measure the total annual cost per patient and total cost per patient virally suppressed (defined as <1000 copies/ml) on antiretroviral therapy in Uganda in five differentiated service delivery models (DSDMs), including facility- and community-based models and the standard of care.
Methods A cost/outcome study was undertaken from the perspective of the service provider, using retrospective patient record review of a cohort of patients over a two-year period, with bottom-up collection of patients’ resource utilization data, top-down collection of above-delivery level and delivery-level providers’ fixed operational costs, and local unit costs.
Results Forty-seven DSDMs located at facilities or community-based points in four regions of Uganda were included in the study, with 653 adults on ART (>18 years old) enrolled in a DSDM. The study found that retention in care was 98% for the sample as a whole [96-100%], and viral suppression, 91% [86%-93%]. The mean cost to the provider (Ministry of Health or NGO implementers) was $152 per annum per patient treated, ranging from $141 to $166. Differences among the models’ costs were largely due to patients’ ARV regimens and proportions of patients on second line regimens. Service delivery costs, excluding ARVs, other medicines and laboratory tests, were modest, ranging from $9.66-16.43 per patient.
Conclusion We conclude that differentiated ART service delivery in Uganda achieved excellent treatment outcomes at a cost similar to the standard of care. While large budgetary savings might not be immediately realized, the reallocation of “saved” staff time could improve health system efficiency as facilities and patients gain more experience with DSD models.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Retrospective data only
Funding Statement
This work was supported by the United States Agency for International Development (USAID) under Cooperative Agreement AID-OAA-A-15-00070 for the EQUIP Project. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. The views expressed in this publication do not necessarily reflect the views of the United States Agency for International Development, the United States Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ugandan TASO Research Ethics Committee (TASOREC/049/18-UG-REC-009) and the Ugandan National Council for Science and Technology (SS4746), and permission was also obtained from the Uganda Ministry of Health to access district health regions and ART sites.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Added results on medication possession ratio (MPR).
Data Availability
The data are owned by the study sites and Ministry of Health (Uganda) and governed by the TASO Research Ethics Committee (Uganda). All relevant data are included in the manuscript and supporting information files. The full data are available from HealthNet Consult (Uganda) for researchers who meet the criteria for access to confidential data and have approval from the owners of the data. Contact the organization representation Ms. Charlotte Muheki (cmuheki{at}gmail.com) for additional information regarding data access.
Abbreviations
- CCLAD
- community client-led ART delivery
- CDDP
- community drug distribution points FBG facility-based groups
- FBIM
- facility-based individual management
- FDR
- fast-track drug refills
- IAC
- intensive adherence counselling
- LTFU
- lost to follow-up
- MMS
- multi-month scripts
- MPR
- medication possession rate
- PLW
- pregnant and lactating women
- VL
- viral load
- VS
- virally suppressed
